SEC Form 4 · accession 0001237899-15-000023
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marc Tessier-Lavigne
Director
Period of report
Feb 26, 2015
Accepted (ET)
Feb 27, 2015 · 4:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 26, 2015 | M | 3,000 | $50.91 | A | 4,187 | D | |
| Common StockF1 | Feb 26, 2015 | S | 1,600 | $420.33 | D | 2,587 | D | |
| Common StockF2 | Feb 26, 2015 | S | 1,100 | $423.64 | D | 1,487 | D | |
| Common StockF3 | Feb 26, 2015 | S | 300 | $424.44 | D | 1,187 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F4 | $50.91 | Feb 26, 2015 | M | 3,000 | D | — | Nov 18, 2021 | Common Stock | 3,000 | 9,279 | D |
Explanation of responses
- F1Represents volume-weighted average price of sales of 1,600 shares of Company stock on February 26, 2015 at prices ranging from $420.10 to $420.57. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2015 at each separate price.
- F2Represents volume-weighted average price of sales of 1,100 shares of Company stock on February 26, 2015 at prices ranging from $423.40 to $423.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2015 at each separate price.
- F3Represents volume-weighted average price of sales of 300 shares of Company stock on February 26, 2015 at prices ranging from $424.00 to $424.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2015 at each separate price.
- F4The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.